The central scientific repository for Limb-Girdle Muscular Dystrophy R4 (LGMD 2E / SGCB deficiency): connecting human clinical genetics, AAV clinical pipelines, in vivo base editing, and cytoprotective peptide biophysics.
Limb-Girdle Muscular Dystrophy R4 (LGMD 2E) is a progressive, life-altering autosomal recessive disease. Families navigating this diagnosis deserve absolute scientific truth, rigorous peer-reviewed evidence, and an unvarnished assessment of translational realities:
*Disclaimer: This repository is compiled for medical scientists, neuromuscular neurologists, geneticists, and custom peptide CRO synthesis chemists. It does not constitute individual medical advice. Never initiate or alter clinical management without consultation with a qualified neuromuscular clinical specialist.
Navigate into specialized deep-dive sections covering molecular genetics, gene therapy pipelines, custom peptide specifications, and live scientific intelligence.
The "House of Cards" sarcoglycan assembly hierarchy, ERAD degradation, and exact molecular analysis of the compound heterozygous Ser114Phe and Tyr184* variants.
SRP-9003 Phase 3 EMERGENE biopsy data, AAVrh74 vector biology, in vivo Adenine Base Editing (ABE) for Ser114Phe, and non-viral SORT LNPs / eVLPs.
Chemical sequences, RCM hydrocarbon stapling, cyclic calpastatin, SS-31, CRO SPPS synthesis criteria (≥98% purity), and synchronized dosing protocols.
Quantitative 5-tier biomarker matrix: Serum CK, Cardiac MRI (T1/ECV), hs-cTnI, TGF-β1, urinary β2-microglobulin, and NSAA motor batteries.
Real-time scientific news feeds connecting to live NCBI PubMed papers, active ClinicalTrials.gov registries, and curated deep-dive clinical reports.
Download the complete 4-page Clinical Dossier (MED-SGCB-2026-CLIN) and benchmark report (BIO-DMD-2026-TR8), plus 10 verified PubMed citations.
Grounding scientific hope in measurable biological realities: how clinical supportive care, AAV gene replacement, precision base editing, and cytoprotective shields intersect.
Full-length 4-page clinical translation report detailing SGCB genetics, ERAD trafficking, calpain cascades, synchronized dosing regimens, and CRO synthesis quality specifications (≥98.0% purity).